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Abstract
Background: Postoperative/adjuvant radiotherapy of advanced gastric cancer involves a large planning target
volume (PTV) with multi-concave shapes which presents a challenge for volumetric modulated arc therapy (VMAT)
planning. This study investigates the advantages of automated VMAT planning for this site compared to manual
VMAT planning by expert planners.
Methods: For 20 gastric cancer patients in the postoperative/adjuvant setting, dual-arc VMAT plans were generated
using fully automated multi-criterial treatment planning (autoVMAT), and compared to manually generated VMAT
plans (manVMAT). Both automated and manual plans were created to deliver a median dose of 45 Gy to the PTV
using identical planning and segmentation parameters. Plans were evaluated by two expert radiation oncologists
for clinical acceptability. AutoVMAT and manVMAT plans were also compared based on dose-volume histogram
(DVH) and predicted normal tissue complication probability (NTCP) analysis.
Results: Both manVMAT and autoVMAT plans were considered clinically acceptable. Target coverage was similar
(manVMAT: 96.6 ± 1.6%, autoVMAT: 97.4 ± 1.0%, p = 0.085). With autoVMAT, median kidney dose was reduced on
average by > 25%; (for left kidney from 11.3 ± 2.1 Gy to 8.9 ± 3.5 Gy (p = 0.002); for right kidney from 9.2 ± 2.2 Gy to
6.1 ± 1.3 Gy (p < 0.001)). Median dose to the liver was lower as well (18.8 ± 2.3 Gy vs. 17.1 ± 3.6 Gy, p = 0.048). In
addition, Dmax of the spinal cord was significantly reduced (38.3 ± 3.7 Gy vs. 31.6 ± 2.6 Gy, p < 0.001). Substantial
improvements in dose conformity and integral dose were achieved with autoVMAT plans (4.2% and 9.1%, respectively;
p < 0.001). Due to the better OAR sparing in the autoVMAT plans compared to manVMAT plans, the predicted NTCPs
for the left and right kidney and the liver-PTV were significantly reduced by 11.3%, 12.8%, 7%, respectively (p≤ 0.001).
Delivery time and total number of monitor units were increased in autoVMAT plans (from 168 ± 19 s to 207 ±
26 s, p = 0.006) and (from 781 ± 168 MU to 1001 ± 134 MU, p = 0.003), respectively.
Conclusions: For postoperative/adjuvant radiotherapy of advanced gastric cancer, involving a complex target
shape, automated VMAT planning is feasible and can substantially reduce the dose to the kidneys and the liver,
without compromising the target dose delivery.
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Background
In the Intergroup Study 0116 (INT-0116) study, adjuvant
chemoradiotherapy (CRT) improved overall survival and
progression-free survival in patients with gastric cancer
compared to surgery alone [1, 2]. The benefit of combined
modality treatment was later confirmed in Asian studies
with D2-resected patients [3–5]. European trials in gastro-
esophageal junction cancers showed survival benefits
compared to surgery with neoadjuvant CRT [6] or peri-
operative chemotherapy without radiotherapy [7, 8].
Randomized trials comparing adjuvant CRT to (periopera-
tive) chemotherapy indicated clinical benefits for CRT in
subgroups, but failed in showing a consistent benefit in
European and Asian trials [3, 5, 9, 10]. Therefore, the role
of adjuvant CRT in gastric carcinoma compared to other
approaches, such as perioperative chemotherapy, is not
yet clearly defined [9]. The use of modern radiotherapy
approaches might improve the risk−/benefit ratio in favor
of radiotherapy in gastric carcinoma. Recent data showed
the feasibility of using intensity-modulated radiation ther-
apy (IMRT) or volumetric modulated arc therapy
(VMAT) for this purpose [3, 10–12]. Postoperative radio-
therapy of advanced gastric cancer involves a large target
volume with multi-concave shapes which presents a chal-
lenge for VMAT planning with a risk of protocol devia-
tions. In a similar setting, radiotherapy for esophageal
carcinoma indicated that the experience of the treatment
planner may largely affect plan quality, as shown by large
differences in plan quality among planners within one
institute [13]. In such a setting, automated treatment plan-
ning might have several advantages, including facilitated
central review in clinical trials as well as improvement of
less experienced treatment planner’s performance.
Over the years, in-house developed as well as commer-
cial algorithms have attempted to automate the trial-and-
error process in order to create optimal plans, reduce user
variability and improve the quality and efficiency of the
resulting plans. Knowledge-based planning uses a model
library of previously generated plans to predict new
treatment plan parameters [14, 15], while multi-criterial
optimization generates a set of Pareto-optimal plans
[16, 17]. Erasmus-iCycle is an optimizer for fully auto-
mated multi-criterial beam profile optimization and
beam angle selection for coplanar and non-coplanar
IMRT, developed at the Erasmus MC Cancer Institute
[18–22]. In combination with the Monaco treatment
planning system (TPS), Erasmus-iCycle is currently
used in clinical practice for IMRT and VMAT plan gen-
eration for prostate, head and neck, cervical and lung
cancer patients [19–22]. Several studies on postopera-
tive gastric cancer patients have dosimetrically evalu-
ated different radiotherapy techniques [23–26]. To our
knowledge, no study has been published considering
the feasibility and advantages of automated treatment
planning for this treatment site. In this study, we inves-
tigated to what extent automated treatment planning
using Erasmus-iCycle results in improved VMAT plan
quality for advanced gastric cancer patients compared
to plan generation by an expert planner.
Methods
Patients
A total of 20 patients with advanced gastric cancer who
received radiotherapy treatment were included in the
study. Clinical details are shown in Additional file 1:
Table S1. Written informed consent was obtained from
all patients for anonymized usage of treatment planning
data. Our study protocol for retrospective evaluation of
automated planning using Erasmus-iCycle was approved
by the ethics committee of Heidelberg University,
Medical Faculty Mannheim (2016-806R-MA).
Treatment plan generation
All manually and automatically generated dual-arc
VMAT plans (manVMAT and autoVMAT, respectively)
were prescribed to deliver a median dose of 45 Gy to the
target in 25 fractions. The primary planning objective
was achieving adequate PTV coverage while maximally
sparing the organs at risk. All plans were generated for
delivery at a VersaHD linear accelerator (Elekta AB,
Stockholm, Sweden), equipped with an Agility multi-leaf
collimator and a photon beam energy of 10 MV.
All manVMAT plans were generated by expert treat-
ment planners with the Monaco TPS, version 5.11
(Elekta AB, Stockholm, Sweden) using template-based
optimization cost-functions. The employed optimization
template is set according to the current clinical guide-
lines used at the Medical University of Mannheim. For
each patient, the optimization cost-functions’ parameters
were iteratively tweaked to improve the dose distribution
and achieve optimal target coverage while respecting
OAR constraints. As explained below, also the final
autoVMAT plans were generated with Monaco, for
which we used the same software version. All Monte
Carlo dose calculations in Monaco were performed
using a 1% dose variance, and a dose grid resolution of
3 mm. A maximum of 140 control points per arc was
allowed. Also the other segmentation settings were kept
identical for manual and automated plan generation.
Automated multi-criterial VMAT plan generation with
Erasmus-iCycle/Monaco
The in-house developed Erasmus-iCycle/Monaco plat-
form for fully automated multi-criteria plan generation
[18–22] was configured to generate clinically deliverable
VMAT plans for gastric cancer. For each of the study
patients, Erasmus-iCycle was used to first automatically
generate a Pareto-optimal plan with clinically favorable
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trade-offs between treatment objectives using a “wish-
list” developed for gastric cancer (as detailed below in
Table 1). Based on this Erasmus-iCycle plan, a patient-
specific Monaco template was then created fully auto-
matically, to be used in the Monaco TPS for automated
generation of a deliverable dual-arc VMAT plan that
mimicked the initial Erasmus-iCycle plan. The applied
wish-list contains constraints to be strictly fulfilled, and
clinical plan objectives with ascribed priorities to be met
as closely as possible or superseded (see Table 1 for
details). Three constraints were used to control the max-
imum dose in the PTV and the patient (i.e., the outline
of the patient’s external surface including the PTV,
delineated OARs and the unspecified tissues), as well as
the dose conformity outside the PTV. In order to
achieve a homogeneous and adequate PTV dose cover-
age, the highest priority objective was given to the PTV
using the Logarithmic Tumor Control Probability func-
tion (LTCP) [27], followed by a shell around the PTV to
ensure a steep gradient outside the PTV (priority 2). In
line with the clinical practice, minimizing the mean dose
in the kidneys was the organ-at-risk (OAR) objective
with highest priority (priority 3), followed by the mean
dose in the liver (priority 4). Subsequently, equivalent
uniform dose (EUD) objectives with volume effect
parameters (k = 6 and 12) [28], focusing on reduction of
the midrange and high dose in the heart and spinal cord
were used (priorities 5 and 6), respectively. To control
the dose conformity and entrance dose, a shell at 18 mm
from the PTV, as well as a skin ring of 21 mm wide from
the body contour towards the patient’s internal were
defined (priority 7). Additionally, dose-volume objec-
tives for the kidneys, liver, and the lungs were used
with lower priorities.
Plan evaluation and comparison
All plans were evaluated by expert radiation oncologists
(FL, JBH, and DB) for clinical acceptability. For fair dosi-
metric plan comparisons, all manVMAT and autoVMAT
plans were first normalized to obtain equal median PTV
dose (i.e., D50% = 45 Gy). In accordance with the Inter-
national Commission on Radiation Units and Measure-
ments Report No. 83, near-minimum and near-maximum
doses (D98% and D2%, respectively) in the PTV were evalu-
ated, from which the homogeneity index (HI = (D2% -
D98%)/D50%) was computed. Additionally, dose conformity
was estimated by calculating the conformity index (CI
= (TVRI)
2/(TV*VRI)), i.e., ratio of the target volume
covered by the reference isodose level (TVRI) to the target
volume (TV) and volume of the reference isodose (VRI).
Quantitative analyses of OAR doses included Dmean, D30%,
D50%, D60% in the kidneys and the liver-PTV, mean and
maximum doses (Dmean, and Dmax) in the spinal cord and
the heart, volumes of the kidneys receiving more than
12 Gy (V12Gy) and 20 Gy (V20Gy) [29], volumes of the
liver-PTV receiving more than 24 Gy (V24Gy) and 30 Gy
(V30Gy), and Dmean in the lungs and volumes of the lungs
receiving more than 5 Gy (V5Gy) and 20 Gy (V20Gy) [30].
In addition, integral patient doses were evaluated by
assessing patient Dmean and volumes receiving V5Gy,
V11.25Gy and V22.5Gy. Estimated treatment delivery time
and total number of monitor units (MUs) for each plan
were also quantified.
From the DVHs, normal tissue complication probabil-
ities (NTCPs) for the kidneys and the liver were esti-
mated using the Lyman-Burman-Kutcher NTCP model
for late effects, considering tolerance dose TD50/5 = 12 Gy,
n = 0.70, m = 0.26 for the kidneys [29], and TD50/5 = 30 Gy,
n = 0.32, m = 0.15 for liver failure [31], where TD50/5 refers
to the dose to the whole organ which lead to complication
in 50% of the population at 5 years, m relates to the
steepness of the dose-response curve, and n represents
the volume effect in the LKB model. For this purpose,
all plans were first normalized to 1.5 Gy per fraction
using α/β = 2.5 Gy.
Table 1 Applied wish-list for automatic VMAT plan generation
for gastric cancer patients
Constraints
Volume Type Limit
PTV Maximum 105% of Dp
PTV Shell 39 mm Maximum 50% of Dp
Patient Maximum 105% of Dp
Objectives
Priority Volume Type Goal Parameters
1 PTV ↓ LTCP 0.4 Dp=45 Gy,
α = 4
2 PTV Shell 3
mm
↓ Maximum 90% of Dp
3 Left and Right
Kidney
↓ Mean 8 Gy
4 Liver ↓ Mean 15 Gy
5 Heart ↓ EUD 15 Gy k = 6
6 Spinal Cord ↓ EUD 25 Gy k = 12
7 PTV Shell 18
mm
↓ Maximum 40% of Dp
Skin Ring ↓ Maximum 25% of Dp 21 mm













Abbreviations: Dp prescribed dose, LTCP Logarithmic Tumor Control Probability, α
cell sensitivity parameter to achieve adequate target coverage, EUD Equivalent
Uniform Dose, k volume parameter
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Differences in dosimetric parameters between man-
VMAT and autoVMAT plans were analyzed using SPSS
software v.21 (SPSS, Inc., Chicago, USA) and presented
as the mean ± 1 standard deviation. Paired two-sided
Wilcoxon Signed-rank tests were performed to assess
statistical significance of observed differences, consider-
ing p < 0.05 statistically significant.
Results
Target volume dosimetric evaluations
All automatically and manually generated VMAT plans
were clinically acceptable and achieved adequate target
coverage. Clinical acceptability of the plans was evaluated
by radiation oncologists with experience in gastric cancer
treatment (JBH, FL and DB). Differences between the
autoVMAT and manVMAT plans in V95% or D98% were
not statistically significant (Table 2). However, autoVMAT
plans exhibited a significantly lower near-maximum dose
in the PTV, resulting in a better target dose homogeneity
(0.09 ± 0.01 vs. 0.10 ± 0.02 (p = 0.003)). For autoVMAT,
the dose conformity was significantly improved as well
(0.91 ± 0.02 vs. 0.88 ± 0.03 (p < 0.001)). As an example,
Fig. 1a shows the resulting dose distributions from the
autoVMAT and manVMAT plans for patient 8. As is
evident from this figure and the corresponding dose-
volume histograms in Fig. 1b, AutoVMAT resulted in
favorable dose conformity and better OAR sparing.
Organs at risk dosimetric evaluations
Figure 2 shows the observed absolute differences in dosi-
metric parameters for each of the study patients. Overall,
autoVMAT plans had more favorable dose distributions,
resulting in reduced dose delivery to the kidneys, liver,
spinal cord, heart and lungs, without deteriorating the
PTV dose coverage (Table 2 and Fig. 2). Median doses
(D50%) to the left kidney, right kidney, and liver-PTV
were significantly reduced by 28% (from 11.3 ± 2.1 Gy to
8.9 ± 3.5 Gy, p = 0.002), 39% (from 9.2 ± 2.2 Gy to 6.1 ±
1.3 Gy, p < 0.001), and 11% (from 18.8 ± 2.3 Gy to 17.1
± 3.6 Gy, p = 0.048), respectively. The V20Gy for the left
and right kidney with autoVMAT were lower than those
for the manVMAT plans (Table 2). In addition, the
V30Gy for the liver-PTV was significantly decreased with
autoVMAT plans by 36% (from 17.7 ± 6.2% to 12.9 ± 6.0%,
p = 0.001). The maximum dose in the spinal cord was on
average reduced by 6.7 ± 3.2 Gy (p < 0.001) with auto-
VMAT. Furthermore, the integral dose in the patient and
the dose conformity were also significantly better with
autoVMAT (Table 2).
NTCPs evaluations
The published sets of parameters used for calculations
of NTCPs for the kidneys and liver-PTV resulted in
overall lower probability of late complications with
Table 2 Comparison of dosimetric parameters between autoVMAT
and manVMAT plans. Population mean values for the 20 study
patients and corresponding standard deviations are reported
Structure Parameter autoVMAT manVMAT – autoVMAT
Mean ± SD Mean diff. ± SD p-value
PTV V95% (%) 97.4 ± 1.0 - 0.8 ± 1.7 0.085
D98% (Gy) 42.5 ± 0.5 - 0.2 ± 0.7 0.14
D2% (Gy) 46.3 ± 0.1 0.5 ± 0.2 < 0.001
HI 0.09 ± 0.01 0.02 ± 0.02 0.003
CI 0.91 ± 0.02 - 0.04 ± 0.03 < 0.001
Left Kidney Dmean (Gy) 12.7 ± 4.3 1.8 ± 1.6 0.001
D30% (Gy) 14.9 ± 8.1 2.1 ± 3.3 0.013
D50% (Gy) 8.9 ± 3.5 2.4 ± 2.2 0.002
D60% (Gy) 7.3 ± 1.9 2.4 ± 1.4 < 0.001
V12Gy (%) 32.2 ± 14.0 11.7 ± 7.7 < 0.001
V20Gy (%) 19.2 ± 13.2 1.0 ± 3.9 0.117
NTCP (%) 45.1 ± 35.8 11.3 ± 10.9 0.001
Right Kidney Dmean (Gy) 7.5 ± 1.7 3.0 ± 1.2 < 0.001
D30% (Gy) 7.8 ± 1.7 4.1 ± 1.6 < 0.001
D50% (Gy) 6.1 ± 1.3 3.1 ± 1.3 < 0.001
D60% (Gy) 5.5 ± 1.2 2.7 ± 1.1 < 0.001
V12Gy (%) 12.4 ± 4.8 18.9 ± 8.4 < 0.001
V20Gy (%) 3.8 ± 2.8 3.0 ± 2.8 0.001
NTCP (%) 4.2 ± 3.8 12.8 ± 7.2 < 0.001
Liver - PTV Dmean (Gy) 18.6 ± 3.3 1.8 ± 2.8 0.02
D30% (Gy) 21.9 ± 4.1 2.8 ± 3.2 0.003
D50% (Gy) 17.1 ± 3.6 1.7 ± 3.3 0.048
D60% (Gy) 15.1 ± 3.4 1.2 ± 3.3 0.14
V24Gy (%) 25.4 ± 11.6 7.1 ± 8.8 0.004
V30Gy (%) 12.9 ± 6.0 4.7 ± 4.6 0.001
NTCP (%) 31.1 ± 23.2 7.0 ± 7.0 0.001
Heart Dmean (Gy) 12.7 ± 4.7 0.7 ± 1.8 0.117
Dmax (Gy) 46.8 ± 0.6 0.8 ± 1.2 0.009
Spinal cord Dmean (Gy) 13.9 ± 2.6 2.9 ± 1.5 < 0.001
Dmax (Gy) 31.6 ± 2.6 6.7 ± 3.2 < 0.001
Left Lung Dmean (Gy) 7.3 ± 3.2 0.6 ± 0.3 < 0.001
V5Gy (%) 32.7 ± 15.6 1.4 ± 1.0 < 0.001
V20Gy (%) 14.0 ± 7.2 2.2 ± 1.8 < 0.001
Right Lung Dmean (Gy) 5.4 ± 3.3 0.3 ± 0.5 0.013
V5Gy (%) 31.2 ± 16.8 1.1 ± 2.1 0.01
V20Gy (%) 7.0 ± 7.6 0.8 ± 1.8 0.078
Patient Dmean (Gy) 9.4 ± 1.9 0.5 ± 0.3 < 0.001
V5Gy (%) 40.2 ± 8.9 1.6 ± 0.8 < 0.001
V11.25Gy (%) 30.0 ± 6.6 1.8 ± 1.7 0.001
V22.5Gy (%) 16.2 ± 3.3 1.5 ± 1.1 < 0.001
Abbreviations: HI homogeneity index, CI conformity index, NTCP normal tissue
complication probability
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autoVMAT compared to manVMAT plans. In 16/20
patients, the predicted NTCPs were lowest with auto-
VMAT for the left kidney, whereas all 20 patients had
lower predicted NTCPs with autoVMAT for the right
kidney (Fig. 3). For 17/20 patients, the NTCP predic-
tions for liver-PTV were lower for the autoVMAT plans.
The average NTCP values resulting from autoVMAT,
given in Table 2, were significantly reduced by 11.3%,
12.8% and 7% for the left and right kidney and the
liver-PTV, respectively.
Planning and treatment delivery times
All manVMAT plans in this study were generated using
template-based manual planning. Hands-on tweaking
time of the optimization cost functions was on average
30 min (range 5-60 min). The optimization and dose cal-
culation of autoVMAT plans in Erasmus-iCycle/Monaco
was fully automated and therefore did not require any
hands-on time.
Compared to manVMAT plans a significantly more
MUs were required for delivery of the autoVMAT plans
(1001 ± 134 MU vs. 781 ± 168 MU, p = 0.003), resulting
in a prolonged (estimated) treatment delivery time (207
± 26 s vs. 168 ± 19 s, p = 0.006).
Discussion
Gastric cancer is the third leading cause of cancer death
in both sexes with yearly 723,000 deaths worldwide [32].
Protocol deviations can reduce clinical efficacy of radio-
therapy in complex treatment geometries, like gastric
carcinoma. In the centralized review of the INT-0116
study, minor or major protocol deviations were observed
in 35% of patients [2]. Even after correction of errors,
major protocol deviations were still found in 6.5% of the
plans that were actually irradiated [1, 2]. The clinical
impact of protocol deviations in INT-0116 has not been
reported. However, in other complex geometries it was
shown that protocol violations during radiation therapy
were correlated with reduced overall survival [33]. Mod-
ern radiotherapy approaches such as IMRT and VMAT
have several dosimetric advantages but they are associ-
ated with increased complexity [9, 34–36]. Very high
protocol deviations are therefore possible; for example,
RTOG 0529 showed 81% protocol deviations at first plan
review [37]. Albeit in small numbers, RTOG 0022
showed local failure rates of 50% (2/4) vs. 6% (3/49) in
oropharyngeal cancer patients treated with and without
protocol deviations, respectively [38]. Protocol devia-
tions may, amongst other things, be caused by inaccur-
ate delineation or sub-optimal treatment planning. For
gastric cancer, the percentage of these deviations is
unknown. In a recent report on RTOG 0933 by Gondi
et al. [39], unacceptable radiotherapy protocol deviations
were observed in 25% of cases at a rapid review process:
11/21 cases had contouring deviations, 5/21 cases had
unacceptable planning deviations and 5/21 had unaccept-
able deviations of contouring and planning. Also in a
recent study of Habraken et al. [40] on hepatocellular
carcinoma patients, it was demonstrated that pretreat-
ment plan review was important to reduce unacceptable
protocol deviations. Additionally, they demonstrated that
automated treatment planning could be used to identify
sub-optimal treatment plans. This might be especially
relevant in trials in which low numbers of patients are
eligible or small numbers of patients are treated in a
participating hospital.
Over the past years, several studies have investigated
the advantages of automated treatment planning com-
pared to manual planning using in-house developed or
commercial algorithms [18–22, 41–43]. Treatment plan-
ning with Erasmus-iCycle/Monaco is fully automated,
Fig. 1 a Comparison of dose distributions for the manVMAT (left)
and autoVMAT plans (right) for patient 8 on the axial, coronal and
sagittal planes, (b) dose volume histograms for the manVMAT (solid
lines) and the autoVMAT (dashed lines) plans of this patient
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and it has been successfully validated for clinical use in
several treatment sites including prostate [19], head-
and-neck [20], cervix [21], and lung [22]. Knowledge-
based planning using a model library of previously
generated plans to predict treatment plan parameters for
a new patient was configured and tested in pelvic anat-
omy [41], lung [42], and esophageal cancer [43].
Numerous dosimetric studied have evaluated different
radiotherapy techniques for gastric cancer by comparing
IMRT, VMAT, helical tomotherapy, 3DCRT and proton
therapy [23–26]. Until now, no study has been published
showing the possibility/advantages of automated treat-
ment planning for postoperative gastric cancer patients.
In this study Erasmus-iCycle was used to automatically
generate VMAT plans for gastric cancer patients. For
this site, manual treatment optimization is a large chal-
lenge, even for an expert planner, due to the multi-
concave shape, the extent of the target volume, and the
close proximity to many radiosensitive organs (i.e., kid-
neys, liver, heart, and spinal cord). Another difficulty in
postoperative radiotherapy in gastric cancer patients is
that radiation tolerance doses of OARs are relatively
low. Compared to the manVMAT plans, generated by
an expert planner, plan quality was significantly better
for the autoVMAT plans, only requiring slightly longer
treatment delivery times. Specifically, dose conformity
and sparing of organs at risk were improved, while the
clinical importance of the observed longer treatment
delivery time and the increased MUs is considered to
be low. As a result of higher modulation, the number
Fig. 2 Differences in dosimetric plan parameters between autoVMAT and manVMAT plans for each of the 20 study patients. Positive values are in
favor of the autoVMAT plans
Fig. 3 Differences in the predicted normal tissue complication probabilities (NTCP) between autoVMAT and manVMAT plans for the 20 study patients.
Positive values are in favor of the autoVMAT plans
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of MUs was significantly higher in the autoVMAT than
in manVMAT plans, this could lead to challenges in
radiation delivery. The integral dose was significantly
reduced in autoVMAT plans, this may be beneficial
specially for young patients to avoid secondary tumors,
and most notably showed significantly reduced NTCP
for liver and both kidneys, although it is not yet clear
to what extent the observed dosimetric advantages of
autoVMAT vs. an experienced planner will really trans-
late into a clinical benefit. Automated treatment plan-
ning can improve the efficiency of the treatment
planning process and reduce its user dependency, this
in turns might lead to more consistent and uniform
outcomes in treatment planning studies and clinical
trials. Apart from the improved plan quality and re-
duced predicted complications, automated planning
also eliminated the planning hands-on time required
for planning.
Conclusion
Automated treatment planning is of great value for com-
plex treatment sites like for gastric cancer. Compared to
manual planning by an expert planner, plan quality
could be largely improved, while drastically reducing
treatment planning workload.
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